Advanced Clinical Services Announces Cheryle Evans as New Vice President, Clinical Operations

Deerfield, IL (August 1, 2013) — Advanced Clinical, a leading provider of clinical research solutions, today announced the addition of Cheryle Evans, RN, Vice President, Clinical Operations to its leadership team. 

Ms. Evans is a tenured leader and will be responsible for strategic planning and tactile operations in project management, clinical monitoring, site activation and document management. Prior to joining Advanced, Cheryle served as Vice President, Clinical Operations for North America with a top 5 CRO, inclusive of study start-up, document management, expedited safety reporting and clinical monitoring. She was also responsible for global oversight of three global strategic service units, in which she led several harmonization and optimization initiatives including the development of a Global Study Start Up team and business process automation. 

"We are very excited that Cheryle has joined the Advanced Clinical team," said Leo Sheridan, CEO of Advanced Clinical. "Cheryle's experience in leading and managing front-end, global Clinical Operations is critical to Advanced's continued growth and success. Her background and expertise in clinical research, as well as her strong leadership and customer service skills, are a perfect fit for Advanced Clinical." 

A graduate of the St. Anne's School of Nursing in Chicago, IL, Ms. Evans is a registered nurse, attended the University of Illinois at Chicago, and has been in the clinical research industry for over twenty five years. Ms. Evans will be based out of Advanced Clinical's headquarters in Deerfield, IL. 


Advanced Clinical is a global, clinical outsourcing organization built around delivering a truly better clinical trial experience. For over 18 years, Advanced has been providing full-service CRO, FSP, and strategic staffing solutions for Pharmaceutical, Biopharmaceutical, Biotechnology, and Medical Device organizations. To learn more, visit 


Kristin Kelley

Associate Director of Marketing

Advanced Clinical


[email protected] 

Suggested Articles

When it’s time to go public, most biotech companies for the Nasdaq. Not so for SQZ Biotech, which raised $71 million in its NYSE debut.

The saga of COVID antibody R&D continues as the REGN-COV2 antibody cocktail used by President Donald Trump has been hit by safety concerns.

A Dartmouth-led team proposed a method for targeting and inhibiting the most aggressive cells in breast tumors to improve responses to chemotherapy.